Institut National De La Sante Et De La Recherche Medicale

Universitè De Montpellier

Centre Hospitalier Universitaire De Montpellier

Inserm (Institut National De La Sante Et De La Recherche Medicale)

Centre Hospitalier Régional Universitaire De Montpellier

Université Montpellier

Inserm

Delphine Haouzi

Samir Hamamah

Said Assou

Gisèle Ouandaogo Zamalou

The invention relates to a method of assessing pregnancy outcome. The inventors investigated endometrial miRNAs associated with pregnancy outcome by studying miRNAs associated with endometrial receptivity, implantation failure and embryo miscarriage. They performed a miRNomic study to find miRNAs that are differentially expressed according to the endometrial receptivity status, compared the endometrial miRNome between receptive patients with negative beta-hCG and receptive patients with positive beta-hCG, and compared the endometrial miRNome between receptive patients with a miscarriage between 8-12 weeks of amenorrhoea and receptive patients with a live birth. They demonstrated miRNA differential expression in endometrial samples according to the pregnancy outcome. Thus, the invention relates to a method of assessing pregnancy outcome of a patient, comprising a step of measuring in a biological sample obtained from the patient the expression level of at least one miRNA selected from the group consisting of miR-455-3 p, miR-4423-3p, miR-4445-3p, miR-3128, miR-3201, let-7b-5p, let-7c-5p, miR-4534, miR-214-3p, miR-15b-5p, miR-424-3p, miR-181a-5p, miR-574-3p, miR-92a-3 p, miR-320c, let-7d-5p, miR-125a-5p, miR-320a, miR-320b and let-7f-5p.

Methods for assessing pregnancy outcome

Disclosed herein are methods and kits for assessing the endometrial receptivity of a patient after controlled ovarian hyperstimulation. More particularly, provided herein is a method for assessing the endometrial receptivity of a patient after controlled ovarian hyperstimulation, comprising a step consisting of measuring the expression level of at least one gene selected from fifteen genes in an endometrial biopsy sample obtained from the patient wherein the genes are FGFBP1, MUC20, TMPRSS3, PRUNE2, HES2, MGST1, ERRFI1, EDN1, SLC17A7, MET, CPT1B, DCDC2, LRRC39, IL18RAP, and FOXP1.

Methods for assessing endometrial receptivity of a patient after controlled ovarian hyperstimulation

The present invention relates to a method for assessing the endometrium receptivity of a patient, comprising a step consisting of measuring the expression level of eleven genes in an endometrial biopsy sample obtained from said patient wherein said genes are MFAP5, ANGPTL1, PROK1, NLF2, LAMB3, BCL2L10, CD68, TRPC4, SORCS1, FST and KRT80.

Methods for assessing endometrium receptivity of a patient

Growing community of inventors

Montpellier, France

Delphine Haouzi